4D Molecular Therapeutics
4D Molecular Therapeutics (4DMT) is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy.
AbbVie
At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of over 75 years in eyecare, we’re proud to offer 125 eyecare products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease and retinal diseases.
ALL-OZU-250122 | April 2025
Find us at
2.B10. 2.B35
Alcon
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With an over 75-year heritage, we are the largest eye care device company in the world, with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in over 50 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.
Find us at
2.B25
Alimera
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.eu
Find us at
2.C56
Altris AI
Altris AI is a web-based Decision Support System built for ophthalmologists to enhance OCT scan interpretation and clinical decision-making. Powered by AI, it detects and segments over 70 retinal pathologies and biomarkers, including early glaucoma, AMD, and diabetic retinopathy. The platform streamlines workflow by rapidly identifying healthy scans, flagging severe abnormalities, and offering progression tracking with visual insights. Altris AI reduces interpretation time, supports accurate diagnosis, and provides confidence in complex cases. By integrating Altris AI into daily practice, ophthalmologists benefit from faster assessments, objective data, and improved patient outcomes—raising the standard of care through advanced, AI-driven diagnostics.
Find us at
3.A41
Amgen
Amgen harnesses the best of biology and technology to make people’s lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what’s known today. We are one of the world’s leading independent biotech companies – fighting the toughest diseases and helping millions of people globally.
Find us at
3.B40
Apellis
Apellis is a global biopharmaceutical company that leverages courageous science and compassion to develop therapies that target the complement system. Apellis is committed to addressing the unmet medical needs of patients and healthcare professionals worldwide, with the goal of slowing progression of geographic atrophy.
Find us at
3.B10
Aprofol AG
Ocufolin® forte - developed by Aprofol AG - is an innovative folate formulation for the eyes. It supports an improvement in retinal microcirculation, a reduction in homocysteine levels in the blood plasma, an improvement in total retinal blood flow and a reduction in increased retinal venous pressure. The effect has been proven by studies.
Find us at
3.D13
Astellas Pharma Inc.
At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater VALUE by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.
Find us at
2.B41